Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…
Recent advances within the medical field have prompted the development of RNA therapeutics for many different applications. These therapeutics have the potential to greatly change the treatment landscape and create…
On April 6, 2022, biotechnology company Dialectic Therapeutics announced via press release that its therapeutic candidate DT2216, designed for relapsed or refractory (R/R) cutaneous T-cell lymphoma (CTCL) or peripheral T-cell…
In a Phase 3 clinical trial, researchers evaluated I/ONTAK (also known as E7777) as a potential therapeutic option for persistent or recurrent cutaneous T-cell lymphoma (CTCL). According to Targeted Oncology,…
A study recently published in the journal Blood Advances has demonstrated that brentuximab vedotin (BV) treatment leads to improved outcomes for primary cutaneous anapestic large-cell lymphoma (C-ALCL) and CD30-expressing mycosis fungoides (MF)…
According to a recent article, a man in Bar Harbor has the entire community behind him as he searches for a stem cell donor for himself and others battling cutaneous…
The FDA has recently announced that they have put a clinical trial for relapsed or refractory T-cell lymphoma patients and cutaneous T-cell lymphoma patients on hold. This trial was a…
The Memorial Sloan Kettering Cancer Center has recently released skincare guidelines and tips for those living with cutaneous T-cell lymphoma (CTCL). It's important that impacted individuals take good care of…
A recent article in Medical Life Sciences alerts physicians to be aware of a deadly skin cancer. It is called cytotoxic cutaneous T-cell lymphoma (CTCL). According to an article in…
Cutaneous T-cell lymphoma (CTCL) is a rare type of cancer with its origin (pathogenesis) found in white blood cells (T lymphocytes). The disease is incurable and debilitating. A recent article…
In a recent news release from global specialty pharmaceutical company Kyowa Kirin International PLC ("Kyowa Kirin"), the company announced the release of new real-world data on POTELIGEO (mogamulizumab) for patients…
782 words (source) vs. 472 words (mine) - 1% match Some rare diseases or rare cancers are exceedingly difficult to treat. For example, for patients with early-stage cutaneous T-cell lymphoma…
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
